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Emerging evidence suggests a strong interaction between the gut microbiota and health and disease. The interactions of the gut
microbiota and the liver have only recently been investigated in detail. Receiving approximately 70% of its blood supply from the
intestinal venous outflow, the liver represents the first line of defense against gut-derived antigens and is equipped with a broad
array of immune cells (i.e., macrophages, lymphocytes, natural killer cells, and dendritic cells) to accomplish this function. In
the setting of tissue injury, whereby the liver is otherwise damaged (e.g., viral infection, toxin exposure, ischemic tissue damage,
etc.), these same immune cell populations and their interactions with the infiltrating gut bacteria likely contribute to and promote
these pathologies. The following paper will highlight recent studies investigating the relationship between the gut microbiota, liver
biology, and pathobiology. Defining these connections will likely provide new targets for therapy or prevention of a wide variety
of acute and chronic liver pathologies.
1. Introduction
Receiving approximately 70% of its blood supply from
the portal vein which is the direct venous outflow of the
intestine, the liver is continually exposed to gut-derived
factors including bacteria and bacterial components. To
combat this influx, the liver contains a large number of
resident immune cells including macrophages (i.e., the
Kupﬀer cell), lymphocytes, natural killer cells, dendritic
cells, and B cells. Together, these immune cell populations
in conjunction with other nonparenchymal cells including
endothelial cells and stellate cells orchestrate a controlled and
organized response to these potentially highly inflammatory
factors. However, when normal liver physiology is disrupted
and inflammatory cells are activated, gut-derived factors
likely augment or exacerbate certain liver diseases leading to
enhanced tissue damage and propagation of inflammation.
Thus, understanding the mechanisms both of control and of
activation by gut-derived factors as well as the functionality
of the gut barrier are critical to the development of new
therapeutic modalities to treat or prevent acute and chronic
liver diseases such as viral hepatitis, alcoholic liver disease,
and/or liver cancer. The current paper will provide an
overview of gut bacterial populations, gut barrier function,
and the potential interactions of gut bacteria with acute and
chronic liver disease.
2. The Gut Microbiome
The human intestine provides residence to 1 × 1013 bac-
teria, a number which dwarfs the total number of cells
in the human body (1 × 1012) [1, 2]. Referred to as
commensal bacteria, these microorganisms play a crucial
role in human physiology and metabolism, providing key
metabolic functions during absorption and waste breakdown
[3]. Moreover, they also contribute to gut epithelial cell
responses including proliferation and diﬀerentiation and
play a key role in barrier development and function [4]. It
is clear, however, that these same luminal contents may also
contribute to intestinal pathology in the setting of colitis
where immune cell dysfunction, barrier disruption, and/or
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overgrowth of pathogenic bacterial species have been shown
to be involved [5–8]. The following sections will provide a
brief overview of the populations present and their proposed
functions.
3. Populations of Microflora
A number of studies have sought to identify the populations
present with estimates of approximately 800 diﬀerent species
[2]. The reasons for these diﬀerences in numbers are likely
the result of mechanism(s) of detection as early studies
used both microscopy and culture where as more recent
studies utilize highly sensitive sequencing approaches of
16 S rRNA for identification including 454 pyrosequencing
[1]. The predominant bacteria present within the gut are
from the genera bacteroides, clostridium, bifidobacterium,
peptostreptococcus, and ruminococcus with escherichia, lacto-
bacillus, enterobacter, and enterococcus constituting a minor
but significant proportion [1, 9]. Interestingly, the types and
proportions of bacteria within the intestine from lower small
intestine to distal colon are diﬀerent, likely regulated both
by the microenvironment (i.e., pH and nutrient availability)
and the intestinal motility itself [10, 11]. For example,
Escherichia coli, enterococci, and lactobacilli account for
greater than 50% of cecal bacteria whereas their numbers
dwindle to less than 10% in the distal colon. The specific
populations present also varies both between individuals and
in the same individual during periods of illness or alterations
in food intake [9]. Indeed, treatment with antibiotics or
acute diarrheal illness have been shown to alter gut microbe
densities and populations while alterations in diet (i.e., high
fiber) may also cause a minor shift in these populations [12].
Alternatively, specific physiological abnormalities may also
contribute to gut bacteria content. For example, pancreatic
exocrine insuﬃciency or vagus nerve defects can reduce
antibiotic factors (i.e., pancreatic enzymes) and peristalisis,
respectively, leading to increased bacterial growth in the
upper gastrointestinal (GI) tract while strictures and adhe-
sions can themselves limit gut content mobility, promoting
bacterial overgrowth [13]. Moreover, in animal models,
significant diﬀerences in gut microbiota have been shown
between vendors and as well as in genetically deficient mice.
For example, significant diﬀerences in both total bacterial
load and specific bacterial populations (i.e., segmented fila-
mentous bacteria) were shown between mice purchased from
Jackson Laboratories and Taconic Farms [14]. In addition,
mice deficient in MyD88, an adaptor molecule associated
with numerous innate immune receptors, showed altered gut
microbiota in the distal intestine suggesting that immune cell
function can interact with and alter luminal bacterial pop-
ulations [15]. Thus, physiological and pathological changes
in intestinal function including alterations in immune
cell responses can significantly influence the proportions,
quantity, and spatial distribution of bacteria present within
the intestine.
The reason for and importance of interindividual diﬀer-
ences in gut microbial content in otherwise normal individu-
als is less clear [16]. The human microbiome project has been
initiated by the National Institutes of Health in the United
States to characterize the bacterial populations present both
within healthy and diseased individuals from all over the
world. Early results demonstrate what appear to be a core
group of bacteria which is shared by most individuals though
the vast majority of bacteria are still heterogeneous among
diﬀerent individuals [16]. Together, it is clear that significant
diversity exists among intestinal bacterial species between
individuals and that certain environmental, physiological,
pathological, or therapeutic interventions can modulate
these populations.
4. Function of the Gut Microflora
As noted above, intestinal microbiota are referred to as
commensal as they coexist without initiating inflammatory
or infectious responses. It is becoming clear that these same
bacteria provide at least three key functions to the mam-
malian intestine including epithelial cell health, nutrient
metabolism and breakdown, and indirect mucosal defense
against pathogenic bacterial strains. Perhaps the most easily
understood function of these bacteria is their contribution
to metabolism and nutrient breakdown. Commonly repre-
sented genera of bacteria within the human intestine are
known to express key polysaccharide metabolizing enzymes
capable of breakdown of routinely consumed sugars includ-
ing cellulose, pectins, and gums [17]. These same bacteria
also aﬀect gut barrier function. Indeed, these nonpathogenic
bacteria compete for nutrients and adherence with other
pathogenic bacteria. A good example of this eﬀect is seen
in experimental animals as well as patients receiving high-
dose antibiotic treatment where reductions in normal gut
flora allow for overgrowth of pathogenic bacteria including
Clostridium diﬃcile [18, 19]. The generation of germ-free
mice has further confirmed the importance of commen-
sal bacteria in health and barrier function. Intragastric
infection of germ-free mice with E. coli O157:H7 resulted
in rapid intestinal colonization and morbidity associated
with glomerular toxicity, a response not observed in con-
ventionalized mice [20]. Again, overgrowth of pathogenic
bacteria in a germ-free host is the likely cause for these
findings though alterations in barrier integrity or immune
cell development, localization, or responsiveness may also
contribute.
Finally, intestinal microbiota also influence epithelial cell
health and function. When biota are absence as in the
germ-free mice, intestinal epithelial cells are underdeveloped
[21, 22]. As discussed above, gut flora play a key role
in metabolism of complex sugars. During this process,
fermentation of sugars forms a number of short chain fatty
acids including proprionate, acetate, and butyrate among
others [1]. Interestingly, intestinal epithelial cells derive a
large percentage of their metabolic fuel from these products,
specifically butyrate. In vitro butyrate administration to
cultured intestinal epithelial cells promotes their survival,
diﬀerentiation, and proliferation thereby supporting barrier
integrity [23]. Together, these studies and numerous others
support a specific and tightly regulated role for enteric
bacteria in metabolism, defense, and barrier integrity within
the intestine.
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5. Gut Barrier Function and Dysfunction
In as much as gut bacteria contribute to normal gut physi-
ology, their presence poses a continuous risk for systemic
infection [6]. The direct physical barrier against bacterial
translocation is complex. Mucous producing goblet cells
secrete a thick layer of polysaccharide called mucin which
coats the intestinal epithelial surface and provides a physical
barrier suppressing epithelial-bacteria contact. This layer
constitutes in part the unstirred layer covering the intestinal
epithelium, slowing the movement of solutes and bulk
fluid through the barrier [24]. The specific importance of
mucins in protection against intestinal inflammation can
be seen Muc2-deficient mice [25]. Mice lacking Muc2 show
increased susceptibility to dextran sodium sulfate-mediated
colitis. Moreover, in humans, polymorphisms in Muc3A
correlate with increased frequency of ulcerative colitis [26].
Thus, the mucous layer is a critical component of the intesti-
nal barrier limiting direct access to the intestinal epithelium.
Below the mucous layer resides the intestinal epithelial
layer. Organized in a crypt and villus arrangement to
increase surface area, intestinal epithelial cells (IECs) are
held together by a series of cell-cell protein interactions
which tightly regulate paracellular solute movement [27].
Nearest the surface of the epithelial cell, claudins interact
with intracellular support provided by zonula occluding
(ZO-1) and F-actin forming the tight junction. Secondary to
the tight junction exists the adherens junction. E-cadherins
attach cell membranes, supported by intracellular catenins
α and β. Near the basolateral surface, the desmosome exists
consisting of desmogleins and desmocollins anchored to
intracellular keratin by desmoplakin [6]. Together, these
three structures support strong epithelial cell contacts and
prevent paracellular movement of large molecules and
bacteria to the underlying tissue.
Despite this tight and redundant barrier, gut bacteria
are continuously sampled by the underlying lamina propria
immune cells. Indeed, this underlying layer contains a
large population of lymphocytes, dendritic (DC) cells, and
neutrophils which serve to intercept invading pathogens
and modify the underlying immune response to commen-
sal bacteria populations. DCs extend projections through
the epithelial layer, sample enteric bacterial antigens, and
present them to underlying lymphocytes, thereby priming
the immune system in case of barrier dysfunction [28, 29]. T
cell development is then regulated by the production of key
cytokines produced by myeloid cells where IL10 principally
contributes to T regulatory cell development and mainte-
nance and suppression of inflammation [7]. However, other
very recent studies indicate that direct interactions of gut-
derived antigens signaling through Toll-like receptor (TLR) 4
on CD4+ T cells contributes to their regulatory development
and function [30]. In summary, the epithelial barrier and
underlying immune cells work together to protect against
translocation, inflammation, and systemic infection.
When this complex barrier and/or underlying immune
cell network is damaged or disrupted, intestinal inflam-
mation, tissue damage, and absorptive dysfunction result.
Key mechanisms in this disruption have been elucidated
and involve immune cell dysregulation, pathogenic bacterial
overgrowth, and/or primary barrier dysfunction. Absence
of interleukin (IL) 10, a key regulatory cytokine, is known
to lead to spontaneous intestinal inflammation in a gut
bacteria-dependent manner [31]. Likewise, reconstitution
of severe combined immunodeficient mice or recombinase
activating gene 1 deficient mice with naı¨ve CD4+CD45RBHi
positive T cells results in significant intestinal inflammation
and barrier disruption again due to dysregulation of lym-
phocyte responses [32]. Infection of germ-free mice with
certain pathogenic strains of Campylobacter can also lead
to mild to moderate intestinal inflammation [33]. Similar
correlations have been established in human inflammatory
bowel disease (IBD) where increased proportions of E. coli
are noted and can be correlated with the severity of disease
[34]. Finally, and as discussed above, alterations in mucin
production predispose the intestine to inflammation and
bacterial translocation. It is likely, however, that in mice
and humans, a combination of factors exist which alter
the intestinal barrier, enhance bacterial translocation, and
promote intestinal inflammation. Nevertheless, key partic-
ipants in the regulation of gut barrier function have been
established and serve as targets for therapeutic intervention.
6. Gut-Liver Interactions in Liver Disease
As the preceding discussion has indicated, gut barrier
function is critical to prevent inflammation of the underlying
mucosa and submucosa. Receiving ∼70% of its blood
supply from the intestine through the portal circulation,
the liver, much like the intestine, is also exposed to gut-
derived factors including bacteria and bacterial products and
thus must be prepared to handle these potential systemic
pathogens. To accomplish this task, the liver contains a large
number of immune cells, of both the innate and adaptive
immune systems which participate both in tolerance and
inflammation within the liver. The following section will
provide a brief overview of these immune cell populations,
including their locations, proportions, and general functions.
7. Hepatic Immunology: An Overview
Perhaps the most characterized of these immune cell
populations is the Kupﬀer cell (KC), the resident hepatic
macrophage. Making up approximately 4% of the total hep-
atic cell population and 80–90% of all tissue macrophages,
KCs are well known for the ability to engulf bacteria and
respond to bacterial antigens including lipopolysaccharide
(LPS) derived from gram negative bacteria such as E. coli
[35]. Through the expression of TLR4 and CD14, KCs are
able to eﬃciently take up endotoxin and phagocytose portally
delivered bacteria while also contributing significantly to
inflammation and tissue damage through the production
of tumor necrosis factor alpha (TNFα) and reactive oxygen
intermediates in a wide variety of acute and chronic liver
disease [36, 37]. Alternatively, KCs may serve to tolerize the
immune response through antigen presentation and con-
comitant nitric oxide and prostaglandin production [38]. It
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is clear given their sheer numbers that KCs are an important
component of the innate immune response of the liver.
Working in concert with these resident macrophages are
DCs. DCs are also capable of engulfing particles includ-
ing bacteria but play a key role in antigen presentation,
cytokine production (i.e., IL4 and 12 production), and T
and B cell development and reactivity [39]. DCs may also
promote natural killer (NK) and natural killer T (NKT)
cell activation via IL12 production and accelerate tumor
cell clearance and their reduced numbers in the hepatitis C
virus (HCV) infected liver may enhance HCV infectivity and
carcinogenicity [40, 41].
Complimenting the functions of KCs and DCs are
those of natural killer (NK) cells. NK cells express specific
receptors (NK1.1, NKG2D in mice; NKp46, CD56, and CD57
in humans) and produce large amounts of perforin and
granzyme B in addition to immunomodulatory factors such
as interferon gamma (IFNγ) and TNFα upon activation
[42, 43]. NK cells are particularly responsive to malignant
or infected cells while also potentially contributing to
transplant rejection and autoimmunity [44, 45]. Indeed,
depletion of NK cells promotes graft survival while their
activation suppresses cancer cell survival and proliferation.
Moreover, NK cells suppress fibrogenesis through direct
killing of hepatic stellate cells (HSCs) in an NKG2D and IFNγ
dependent manner [46].
Bridging the gap between innate and adaptive immunity
is the natural killer T (NKT) cell. Expressing receptors for
both innate (NK1.1, CD49b, CD56, and CD57) and adaptive
(T cell receptor) immune cells, NKT cells represent an
important source of IFNγ and IL4 within the liver [47].
A large proportion of hepatic NKT cells recognize antigens
presented through the MHC Class I-like receptor CD1d, rely
heavily on IL12 and IL15 for survival and activation, and
contribute both to the regulation of T helper (Th) cytokine
production and to acute and chronic liver injury through
cytokine production and Fas expression [48–50]. Much like
NK cells, activation of NKT cells results in tumor cell
clearance while also contributing to early alcohol-induced
liver injury [50, 51].
Fulfilling the adaptive immune functions within the
liver are a large population of traditional CD4+ and CD8+
lymphocytes. Constituting approximately 35% of the hepatic
lymphocyte population, these cells play a key role both in
antigen recognition and in tolerance [52]. Accumulation
and/or survival of hepatic T cells is associated with worse
fibrogenesis while their early accumulation in the ischemic
liver is a known trigger for neutrophil infiltration and tissue
damage [53, 54]. CD8+ T cells contribute to stellate cell
activation during carbon tetrachloride induced fibrosis and
directly damage hepatocytes in the HCV-infected liver in an
antigen specific manner [55, 56].
In summary, and as is shown in Figure 1, the liver
provides residence to a large and heterogeneous population
of immune cells, each with specific functions of protection,
tolerance, and/or inflammation. It is this third aspect,
during inflammatory responses or chronic injury, where the
function of hepatic immune cells is perhaps most interesting
and extensively studied. And of even greater interest is
the potential impact which gut-derived factors may have
on this process. As noted earlier, the liver is a unique
position where its normal function to sample, metabolize,
synthesize, and/or degrade both absorbed and circulating
products also places it in potential direct contact gut-derived
bacteria and bacterial antigens. And previous studies would
suggest that a connection exists as either small intestinal
bacterial overgrowth or infection with helicobacter alone
contributed to hepatic pathology including increased serum
alanine aminotransferase release and inflammatory cell
recruitment [57–59]. Likewise, experimental colitis models
in rodents and inflammatory bowel disease in patients were
associated with periportal inflammation similar to that seen
in primary biliary cirrhosis and primary sclerosing cholan-
gitis, respectively, suggesting that gut-derived factors likely
activate inflammatory processes within the liver [60, 61].
The following sections will highlight the current knowledge
regarding the influence of gut-derived factors on hepatic
biology and pathobiology, focusing on several important
mechanisms of liver injury.
8. Gut Bacteria and the Undamaged Liver
The contribution of gut bacteria to the formation of the
hepatic immune system has not been intensively investigated.
It is clear from the previous discussion that the liver contains
a large number of immune cells though the specific mech-
anisms governing their localization is not well understood.
Crispe and colleagues identified TLR4 as a potential indirect
regulator of activated CD8+ T cell trapping within the
murine liver suggesting a potential interrelation between the
gut antigens, specifically endotoxin, and liver lymphocyte
populations [62]. Recent studies from our laboratory were
directed at better understanding the connection between gut
bacteria and resident hepatic immune cells. Using germ-
free C57Bl/6 wild type mice or specific pathogen free (SPF)
mice, we demonstrated that gut bacteria have little eﬀect on
the proportions of or total numbers of lymphocytes (CD4,
CD8, NK, or NKT cells) or macrophages present within
the murine liver. Moreover, examination of serum alanine
aminotransferase levels and basal expression of key inflam-
matory cytokines including TNFα and antiinflammatory
cytokines (i.e., IL10) were not diﬀerent between germ-free
and SPF mice (Son and Hines, unpublished observation).
Finally, analysis of basal hepatocyte proliferation revealed no
substantial diﬀerences between these groups. Together, these
data demonstrate that resident hepatic immune cells and
hepatocytes themselves are not overtly aﬀected by normal
gut-derived antigen exposure.
While gut bacteria do not significantly aﬀect liver phys-
iology or immune cell populations, its potential to initiate
and/or propagate liver injury has been investigated. For
example, experimental damage of the intestine with dextran
sodium sulfate (DSS) leads to periportal liver inflammation
likely the result of increased gut bacterial delivery to
the liver [63]. Similarly in patients with ulcerative colitis
there is often evidence of primary sclerosing cholangitis
including significant periportal inflammation [64]. Thus,
it is clear that a relationship exists between gut barrier
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Figure 1: Diagramatic representation of the liver sinusoid. HA; hepatic artery. BD; bile duct. PV; portal vein. DC; dendritic cell. KC; Kupﬀer
cell. NKT; natural killer T cell. T; T cell. NK; natural killer cell.
function and secondary liver inflammation. The following
sections will provide a review of the current understand-
ing of gut-derived factors in a number of primary liver
pathologies.
9. Alcoholic Liver Disease (ALD)
Perhaps the best characterized model of liver disease which
is nearly completely dependent on gut-derived factors for
its pathogenesis, chronic alcohol consumption remains an
important clinical problem alone and in combination with
other liver diseases [65]. Early clinical studies revealed
increased plasma endotoxin levels following acute ethanol
exposure in patients with and without chronic liver disease
suggesting that ethanol could potentially alter gut barrier
function [66]. Experimental studies confirmed these findings
identifying the ability of alcohol to injure the rodent liver
through augmentation of gut-derived bacterial translocation
(specifically increased periportal levels of LPS) and specific
activation of Toll-like receptor 4 on KCs [67–70]. Indeed,
sterilization of the gut, depletion of KCs, or mutation
in TLR4 caused a near complete inhibition of ethanol-
induced liver injury as characterized by serum alanine
aminotransferase release, inflammatory cell infiltration, and
hepatocellular lipid accumulation. This central role for
endotoxin in the pathogenesis of early ALD could not be
argued though the mechanism by which ethanol altered gut
permeability was less clear. Consumed ethanol is rapidly
absorbed by the upper GI tract with near complete absorp-
tion occurring by the mid-jejunum. However, the majority
of bacteria are held, as described earlier, within the cecum
and upper large intestine. Careful studies have demonstrated
the ability of ethanol to suppress endotoxin uptake by
KCs and the function of acetaldehyde, the principle by-
product of ethanol metabolism, to directly interfere with
tight junction and adherens junction support [71, 72].
Indeed, absorbed circulating ethanol directly inhibits phago-
cytosis of macrophages including KCs thereby limiting LPS
clearance while acetaldehyde promotes ZO-1 dissociation
from occludin and E-cadherin adherence to β-catenin [73,
74]. Further compounding these eﬀects is the ability of gut
bacteria to metabolize ethanol and thus increase the luminal
concentration of acetaldehyde and the potential for bacterial
overgrowth to occur in ethanol consuming individuals [71,
75]. Thus, gut bacteria play a key role in early alcohol-
induced liver injury both through the metabolism of ethanol
and through the activation of key hepatic innate immune
cell populations. Key questions remain, however, including
the net eﬀect of ethanol on the gut microbiota and the
influence of gut-derived antigens on the progression of ALD,
specifically fibrogenesis.
10. Nonalcoholic Fatty Liver Disease (NAFLD)
NAFLD continues to increase in westernized countries.
Once considered a benign event, accumulation of lipid
within the liver is a known risk factor for the development
of inflammation and fibrosis and a component of metabolic
syndrome, insulin resistance, and obesity [35]. The
mechanism(s) underlying the development of NAFLD are
not well understood, though obesity is a key risk factor.
Numerous studies have implicated liver TNFα as a potential
regulator of its development and TNFα levels are elevated
in several models of NAFLD in rodents and in patients with
NAFLD [76, 77]. Likewise, deficiency in leptin is known
to result in hepatic lipid accumulation in conjunction with
peripheral obesity [48, 78]. The potential influence of gut
bacteria on the development of hepatocellular steatosis has
been postulated. Models of bacterial overgrowth have shown
promise as an initiator of fatty liver and patients with NAFLD
present with upper intestinal bacterial overgrowth and
enhanced intestinal permeability [79, 80]. Consistent with
gut-derived endotoxin mediating these eﬀects, TLR4-mutant
mice showed reduced lipid accumulation following feeding
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text.
a high-fructose diet or methionine-choline deficient diet
when compared to their TLR4-wild type controls suggesting
that LPS may contribute to disease progression [81, 82].
Studies from our laboratory and others have confirmed
enhanced sensitivity of the liver to endotoxin treatment
suggesting that hepatic immune cells, likely KCs, are primed
to respond with increased production of TNFα and IL12
[49]. Similarly, TLR9 signaling may also promote NAFLD.
Miura and colleagues demonstrate a significant reduction
in hepatic lipid accumulation in choline deficient, amino
acid defined diet in TLR9-deficient mice when compared to
their wild type controls, a process which appears to involve
TLR9-dependent Kupﬀer cell activation and subsequent
production of IL1β [83]. Thus, both cell wall components
and DNA derived from bacteria could be involved in the
disruption of normal hepatocyte function in the setting of
NAFLD.
While the above mentioned studies have focused on
the direct interactions of gut-derived bacteria and bacterial
products, the potential influence of certain metabolites of gut
bacteria including short-chain fatty acids on hepatic energy
homeostasis has not been thoroughly explored. It is clear that
gut bacteria provide important metabolic functions, metab-
olizing complex sugars into short-chain fatty acids including
proprionate and acetate, two molecules which are key sources
of energy for the liver and muscle, respectively [1]. This
important function is reinforced by findings in germ-free
mice which are substantially leaner than their colonized
counterparts. The specific mechanism by which SCFAs aﬀect
energy balance is not entirely clear though increased delivery
of short chain fatty acids to the liver and the periphery could
disrupt normal metabolic processes, specifically reducing
glucose utilization and promotion lipid storage. However,
high levels of propionate derived from fiber metabolism
inhibit cholesterol and fatty acid biosynthesis in rodent livers
[84]. Moreover, high-fat diet feeding supplemented with
fermentable dietary fiber reduces plasma endotoxin levels
when compared to high-fat diet feeding alone suggesting that
fiber may aﬀect the gut microbiota and potential influence
intestinal barrier function [85–87]. Thus, the net eﬀect of the
gut microbiota on nutrient and energy balance is complex
and warrants further investigation as it is likely to contribute,
in addition to the direct eﬀects on hepatic cells, to hepatic
lipogenesis, endotoxemia, and NAFLD.
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11. Ischemic Liver Injury
Liver transplantation remains the primary treatment for
a number of chronic liver diseases including cirrhosis.
Organ preservation and associated ischemic tissue damage
represents an important determinant of graft survival.
Critical mechanism(s) in reperfusion injury have been
delineated and include early CD4+ lymphocyte recruitment,
KC activation and subsequent TNFα production, and later
neutrophil recruitment and hepatocellular damage [54, 88,
89]. The contribution of gut bacteria to these processes
has not been thoroughly investigated though it is clear that
bone marrow derived cells and Kupﬀer cells and TLR4 are
critical for early tissue damage following warm ischemia and
reperfusion injury [88, 90–92]. It is also well established
both experimentally and perhaps more so clinically that
intestinal injury occurs during liver surgery and transplan-
tation. Congestion of the portal vein due to clamping,
even intermittently during transplantation or resectional
surgery, reduces barrier integrity and promotes bacterial
translocation [93]. Supporting the impact of intestinal
microbiota directly, gut sterilization suppresses transplant-
induced liver injury in rodents and reduces the incidence of
sepsis early following transplantation in patients suggesting
that intestinal microbiota are involved in these processes
[94, 95].
12. Hepatocellular Carcinoma
The occurrence of hepatocellular carcinoma (HCC) contin-
ues to rise clinically. Both environmental and genetic factors
have been implicated in its initiation. While susceptibility
genes have been identified and range from immune cell
markers to traditional tumor suppressor genes, the potential
environmental cues are less well established [96]. It is clear
that certain hepatotoxins including nitrites, organochlorine
compounds, and aflatoxin contribute significantly to its
development as do preneoplastic injuries associated with
HCV infection [97–99]. The particular contribution of
gut bacteria to the development and progression of HCC
remains somewhat unclear. Gut bacteria convert intestinal
nitrates to nitrites and nitrosoamines which are linked to col-
orectal cancer [1]. Moreover, recent studies have highlighted
the ability of helicobacter hepaticus to promote aflatoxin-
induced HCC in mice, a process involving inflammatory and
proproliferative cytokine production [100]. These studies
correlate well with findings in humans where helicobacter
sp. can be both cultured from the liver and shown to be
in greater quantities in the intestine [58, 101, 102]. Thus,
bacterial metabolism of ingested materials and byproducts
as well as inflammatory responses to the bacteria themselves
likely play critical roles in liver cancer development and/or
progression.
13. Liver Fibrosis
Chronic liver injury arising from a number of etiologies
ranging from chronic ethanol consumption to viral infection
is associated with increased risk for the development of
fibrosis, cirrhosis, and liver failure [103]. It is clear from
a large body of experimental work that repeated and
continuous hepatocellular damage leads to the activation
of HSCs and their production of key extracellular matrix
proteins, specifically Type I fibrillar collagens. A number of
studies have implicated immune cell activation, specifically
macrophages and lymphocytes, in the initiation and propa-
gation of disease [55, 104, 105]. Indeed, depletion of T and
B lymphocytes or macrophages significantly reduced carbon
tetrachloride-induced liver injury [104, 105]. The specific
role which gut-derived antigens play in the setting of fibrotic
liver disease has recently been examined [104]. Sterilization
of the gut prevented both toxin-induced and cholestasis-
induced hepatic fibrosis [104]. Further characterization
revealed a critical role for gut-derived endotoxin as mice
deficient in either CD14 or Toll-like receptor 4 were protected
from cholestasis-induced fibrogenesis [104, 106]. Indeed, it
appears that toxin-induced tissue injury, either by carbon
tetrachloride or cholestasis, leads to increased portal delivery
of endotoxin, activation of hepatic macrophages, induc-
tion of growth factor production, specifically transforming
growth factor beta, and subsequent HSC activation [104,
106]. Moreover, recent studies also highlight the ability of
endotoxin to directly activate HSCs further amplifying the
fibrogenic response in these models [107, 108]. Together, it
is clear that gut microflora, and specifically gram negative
bacteria, contribute to fibrosis induction and progression
experimentally.
The process of fibrogenesis may itself promote bacterial
overgrowth and barrier dysfunction. Cirrhotic patients are
at increased risk for spontaneous bacterial peritonitis in
conjunction with reduced blood flow through the portal
vein, intestinal vascular congestion, and barrier leakiness
[109, 110]. Additionally, fibrosis and associated defective
liver function itself may promote changes in bacterial
populations, intestinal motility, and nutrient absorption and
availability. For example, decreased bile acid production by
the cirrhotic liver is associated with bacterial overgrowth
[111]. Indeed, bile acids play a critical role in regulation
of bacterial survival within the intestine [112]. Bile acids
are directly, though weakly, bacteriocidal but are capable
of activating specific bile acid receptors including farnesoid
X receptor which regulates the expression of key bacteri-
ocidal genes including inducible nitric oxide synthase and
IL18 within the intestine [113]. Cirrhosis also limits small
intestine motility which has been associated with bacterial
overgrowth [110]. Finally, decreased absorption increases
nutrient availability throughout the small and large intestine
further enhancing bacterial growth [114]. Together, it is clear
that hepatic fibrosis is critically regulated by gut-derived anti-
gens and that cirrhosis itself may influence the populations
of bacteria present within the intestine promoting a positive
feedback loop perpetuating tissue injury and fibrogenesis.
14. Autoimmune Liver Diseases
Autoimmunity is associated with several forms of chronic
liver damage including autoimmune hepatitis, primary
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biliary cirrhosis, and primary sclerosing cholangitis. The
initiating events in these diseases are not well understood
though it is clear that antibody formation to self antigens is
key to the development. The influence of the gut microbiota
on these disease processes again has not been thoroughly
investigated though some connections have been suggested.
Autoimmune hepatitis (AIH) accounts for approximately
20% of chronic hepatitis in Caucasians and is characterized
by hypergammaglobulinemia and liver-directed autoanti-
bodies resulting in large hepatic lymphocytic infiltrates
[115]. Activation of hepatic T lymphocytes with the plant
lectin Concanavalin A leads to the expression of key T helper
cytokines including IL4 and IFNγ, macrophage activation,
neutrophil recruitment, and hepatocellular injury similar to
that observed in autoimmune hepatitis [116]. It is clear from
this model system that interruption in the early expression of
either IL4 or IFNγ or disruption in Fas-FasL signaling protect
the liver from this T cell-mediated tissue injury [117–121].
The contribution of gut bacteria to this response has not been
thoroughly investigated. Previous studies have demonstrated
the contribution of TLR4 signaling to the trapping of CD8+
T cells within the murine liver [62]. More recently, TLR9 was
shown to contribute to the homing and activation of hepatic
NKT cells, a process dependent on KCs and IL12 [51]. Simi-
larly, TLR4 expression on intestinal CD4+ T cells contributed
to the induction of T regulatory cells and suppression of
colitis resulting from absence of IL10 [30]. Thus, T cells
appear to be capable of responding to conserved antigens
such as endotoxin directly and this cascade likely contributes
to their responsiveness within the liver. Consistent with
this notion, recent studies in our laboratory demonstrate
the necessity of gut-derived bacteria during ConA-induced
T cell-mediated hepatitis (Son and Hines, unpublished
observation). Absence of gut bacteria significantly reduced
ConA-induced liver injury in the absence of major alterations
in resident T cell number or activation. Indeed, absence of
gut bacteria-reduced early IFNγ and IL4 production, and
later eosinophil recruitment and hepatocellular apoptosis.
Together, these studies suggest that gut-derived products
regulate, either directly or indirectly, T cell function within
the liver. Further study will be required both in animal
models and in patients with AIH to more specifically
delineate the mechanism governing these responses.
Similar to AIH, primary biliary cirrhosis aﬀects approx-
imately 40 per 100,000 people in the United States and
is a consequence of immune cell activation and directed
damage to cholangiocytes, specifically intrahepatic bile
ducts with nearly 95% of patients presenting positive for
antimitochondrial antibodies [115]. Progressive intrahepatic
biliary tract damage promotes bile acid buildup, stellate cell
activation, and hepatic fibrogenesis with failure occurring
in 26% of patients within 10 years of diagnosis with liver
transplantation constituting the primary treatment. Thus,
understanding the factors which may promote or exaggerate
this process are needed. Studies by Hopf and others detailed
an association of E. coli rough form and the presence of PBC
in patients as healthy individuals rarely show measurable
levels of this bacterial subspecies. Moreover, they demon-
strated the presence of lipid A within the liver of PBC but not
healthy control patients further demonstrating the presence
of bacteria within the liver [122]. Given this association,
further study is warranted to determine if modulation of gut
microbiota, particularly E. coli subpopulations might aid in
the treatment of this complex disease.
Very similar to PBC, primary sclerosing cholangitis can
be described as a progressive autoimmune disease process
leading to destruction of intrahepatic and extrahepatic
bile ducts, inhibition of bile acid secretion, toxin buildup,
and chronic hepatocellular injury [123]. Interestingly, as
mentioned previously [64, 115], a large number of patients
(∼75%) show signs of inflammatory bowel disease sug-
gesting potential interactions of the gut and liver and/or
common pathological causes (i.e., autoimmune disorders,
defective immune cell regulation). Experimental models
of inflammatory bowel disease have been associated with
periportal inflammation suggesting potentially that gut
factors may initiate the response in the absence of underlying
immune cell dysfunction [124]. Further examination of
the gut microbiota in conjunction with PSC may unlock
new information into the mechanisms of PSC and aid in
therapeutics development.
15. Viral Hepatitis
Hepatitis arising primarily from HCV infection represents
the leading cause of liver disease in the world [125]. Indeed,
hepatitis B and C viral infections account for 75% of the cases
of liver disease worldwide [126]. The pathogenesis, particu-
larly of HCV infection, is complicated and involves primary
hepatocyte infection, disruption of immune cell responses
including inhibition of endogenous antiviral responses and
activation of adaptive immunity including antigen specific
CD8+ T cell recruitment [126]. The contribution of gut-
derived antigens to the pathogenesis of viral hepatitis has not
been explored. HCV infection is associated with a number
of hepatic diseases from hepatocellular lipid accumulation
to stellate cell activation, immune cell recruitment, and
cancer development. To this third end, very recent studies
by Machida and colleagues identify an important connection
between ethanol consumption, viral infection, TLR4 sig-
naling, and carcinogenesis within the murine liver. Indeed,
TLR4 signaling promotes Nanog/CD133 production and
promotes ethanol/HCV-induced hepatic tumor formation
[127]. Future study in this complex system using rodent
models is warranted to better understand the overall impact
of gut bacteria to the multiple pathologies present. Indeed,
it could be that gut-derived antigens serve to prime hep-
atic innate immune cells to produce important antiviral
cytokines including IFNγ while also promoting hepatic T cell
function and responsiveness. Further study is warranted to
dissect out the potential multiple pathways of involvement of
gut-derived antigens in this complex injury scenario.
16. Concluding Remarks
From the above discussion, it is clear that gut bacteria
contribute to normal intestinal epithelial cell biology and
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function while also contributing substantially to the break-
down of complex sugars in the diet. It is also evident
that these same bacteria, in the absence of appropriate
immune cell regulation or when gut barrier function is
impaired, contribute significantly to intestinal inflammation
and damage. Likewise, these same antigens, when delivered
to the liver, contribute significantly to various acute and
chronic liver diseases through activation of both innate and
adaptive immune responses and wound healing processes.
Thus, modulation of the gut microbiota may represent a
new avenue for therapeutic intervention to treat or prevent a
variety of liver diseases. As detailed in Figure 2, key questions
remain, however, including (1) what are the specific popula-
tions of bacteria present within the intestine and can these be
correlated with or used as a screening tool for the progression
of liver disease, (2) how do diﬀerent microbiota populations
influence gut barrier integrity, and (3) what are the cell-
specific eﬀects of gut-derived antigens within the injured
liver (i.e., KC, stellate cell, T cell, endothelial cell, etc.) and
does the type of injury influence their eﬀects (i.e., ischemic
damage versus viral infection). Future studies directed at
these questions will provide important new information into
the connection between the gut microbiota and liver disease
and likely contribute to new therapies for or predictors of
liver pathobiology.
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